Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Has Average Price Target of $39.50 According to Analysts

Key Points

• Analysts rate Genmab “Moderate Buy”, with nine buy ratings, one strong buy and three holds. The average 12-month price target is $39.50, above the stock’s reported $35.67 opening price.
• Genmab’s latest quarterly results exceeded expectations, with earnings per share of $0.54 versus the $0.37 consensus estimate and revenue of $1.16 billion versus $1.12 billion expected.
• Institutional investors and hedge funds have increased their positions, with institutional ownership reported at 7.07%. The stock was trading near its one-year high of $35.91, with a market capitalization of approximately $22.26 billion.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $39.50.

Several equities analysts recently issued reports on the stock. TD Cowen raised shares of Genmab A/S from a "hold" rating to a "buy" rating and lifted their price objective for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. New Street Research set a $43.00 target price on shares of Genmab A/S in a research report on Wednesday, July 22nd. Weiss Ratings raised Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research report on Tuesday, September 1st. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Genmab A/S in a research note on Monday, September 14th. Finally, Guggenheim lifted their price target on Genmab A/S from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Friday, August 7th.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $35.67 on Thursday. The firm's 50 day simple moving average is $32.54 and its 200-day simple moving average is $28.86. The firm has a market cap of $22.26 billion, a PE ratio of 28.09, a price-to-earnings-growth ratio of 1.93 and a beta of 0.84. Genmab A/S has a one year low of $23.62 and a one year high of $35.91. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. As a group, equities analysts predict that Genmab A/S will post 1.21 EPS for the current year.

Institutional Trading of Genmab A/S

A number of hedge funds have recently modified their holdings of the stock. WINTON GROUP Ltd raised its position in Genmab A/S by 158.9% during the second quarter. WINTON GROUP Ltd now owns 40,900 shares of the company's stock valued at $1,124,000 after acquiring an additional 25,100 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company's stock valued at $153,324,000 after acquiring an additional 1,334,919 shares during the period. SummitTX Capital L.P. purchased a new stake in Genmab A/S in the 1st quarter worth approximately $2,263,000. Diversify Wealth Management LLC purchased a new stake in Genmab A/S in the 1st quarter worth approximately $1,216,000. Finally, First Trust Advisors LP grew its stake in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company's stock worth $66,038,000 after purchasing an additional 1,126,069 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab's portfolio includes products developed through partnerships as well as internally discovered candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.